Skip to main content

CBD In Food & Beverage: Three Developments To Watch In 2020

Hand holding pipette with CBD oil on wooden table

While products containing CBD are widespread, new legal developments are expected in 2020 that may … [+] affect how the products are marketed and sold in certain jurisdictions.

Getty

The cannabidiol (CBD) industry saw considerable growth in 2019, and the industry is expected to see further expansion over the new year. In the absence of clear federal guidance, sellers of products containing CBD, particularly those in the food and beverage space, should watch how three developments might affect their products and the industry as a whole.

  • Further FDA Clarification: The U.S. Food and Drug Administration (FDA) announced in November 2019 that the agency had numerous “unanswered questions and data gaps about CBD toxicity” and issued over a dozen warning letters to sellers of CBD-containing products. The FDA’s updated Consumer Update declared that marketing CBD “by adding it to a food or labeling it as a dietary supplement” is illegal. In its announcement, the FDA noted that it is continuing to explore “potential pathways for various types of CBD products to be lawfully marketed” and expects to provide an update on its “progress regarding the agency’s approach to these products in the coming weeks.” After the agency’s November announcement and warning letters, manufacturers of CBD products, particularly those in food and beverage categories, should watch how the FDA clarifies and enforces its position on CBD-containing products over the new year.
  • State and Local Action: Without clear federal guidelines, states have created a regulatory patchwork of often conflicting rules across the country. As one headline put it: “Headaches abound as states try to clarify [the] CBD landscape.” Some states, such as Maryland, have declared it illegal to add CBD to food products. Similarly, New York City regulators have embargoed food and drink products containing CBD. Media reports note that City officials have ordered at least five restaurants to stop selling CBD-containing food and drink products and that enforcement of the embargo includes fines ranging from $200 to $650. For 2020, the industry should watch how states continue to take action in the absence of clear federal guidance. For example, New York State recently passed a new law, effective in March 2020, that establishes a regulatory framework for the sale of CBD-containing products in the state.  State officials are expected to issue new regulations fleshing out the law in the coming weeks.
  • Class Action Litigation: Given the ambiguity around applicable rules surrounding CBD-containing products, particularly those in the food and beverage industry, private party litigation is expected to increase in the coming year. Already several federal class action lawsuits have been lodged against manufacturers of CBD products alleging that the products are “illegal to sell” and therefore violate state consumer protection laws.   While the CBD industry has expected an “avalanche” of class action cases for some time, the already-filed class action lawsuits suggest that the “CBD lawsuit floodgates are opening.”

Federal and state regulators are contemplating further action over the coming year. So too are additional private party plaintiffs, who are poised to present putative class action allegations given the “language of the FDA’s recent pronouncements and the widespread availability of CBD-containing products.” Manufacturers of CBD-containing products, particularly those in the food and beverage space, should be aware of these developments over the coming year.

Original Article Source: https://www.forbes.com/sites/tommytobin/2020/12/31/cbd-in-food–beverage-three-developments-to-watch-in-2020/

Comments

Popular posts from this blog

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...

A Dozen US Governors Ask Congressional Leaders To Back Federal Marijuana Reform

A bipartisan coalition of 12 governors from states that have legalized medical or recreational cannabis  sent a letter to congressional leaders, asking for their support in getting a major marijuana reform bill through the U.S. House and Senate. The governors of California, Colorado, Maryland, Massachusetts, Nevada, New York, North Dakota, Oregon, Pennsylvania, Utah, Vermont and Washington state are backing  the STATES Act  – which would codify in federal law that marijuana regulations are to be left to the states instead of the federal government – while also seeking protections on banking and tax issues for the MJ industry. “The STATES Act is not about whether marijuana should be legal or illegal; it is about respecting the authority of states to act, lead and respond to the evolving needs and attitudes of their citizens,” the governors wrote. The letter also expressed support for the SAFE Banking Act , which was approved in March by a House committee. Tha...

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...